{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"194-613-449-750-790","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"194-613-449-750-790"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11624,"type":"PATENT","title":"Mayo Medical School - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5667,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8299,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: mayo medi*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5671
Search Applicants and Owners separately: mayo medi*
Select more for logical variants. Add to collection.
Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5671
contacting a sample of pancreatobiliary cells from the patient with a set of detectably labeled probes comprising a locus-specific probe for MCL1 (myeloid cell leukemia sequence 1), a locus-specific probe for EGFR (epidermal growth factor receptor), a locus-specific probe for MYC, and a locus-specific probe for P16 under hybridization conditions and\n
determining the presence of chromosomal abnormalities,\n
wherein polysomy is indicative of high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract, whereas tetrasomy, P16 loss, single locus gain of MCL1, MYC or P16, or single locus gain of MCL1, EGFR, or MYC with concurrent P16 loss infers increased risk of high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract,\n
whereupon high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract in the patient is detected or an increased risk thereof is inferred."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein polysomy in ≧4 cells is indicative of high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract and tetrasomy in ≧11 cells, loss of P16 in at least 5% of cells, single locus gain of MCL1, MYC or P16 in ≧8 cells, or single locus gain of MCL1, EGFR, or MYC with concurrent P16 loss ≧4 cells infers increased risk of high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["A set of probes comprising a locus-specific probe for MCL1 (myeloid cell leukemia sequence 1), a locus-specific probe for EGFR (epidermal growth factor receptor), a locus-specific probe for MYC, and a locus-specific probe for P16."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["A kit comprising:\n
(a) a set of probes that enables detection of pancreatobiliary cancer in a patient, wherein the set of probes comprises a locus-specific probe for MCL1 (myeloid cell leukemia sequence 1), a locus-specific probe for EGFR (epidermal growth factor receptor), a locus-specific probe for MYC, and a locus-specific probe for P16 and\n
(b) instructions for detecting pancreatobiliary cancer in a patient, wherein the instructions comprise determining in a sample of pancreatobiliary cells obtained from the patient the presence of chromosomal abnormalities,\n
wherein polysomy is indicative of high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract whereas tetrasomy, P16 loss, single locus gain of MCL1, MYC or P16, or single locus gain of MCL1, EGFR, or MYC with concurrent P16 loss infers increased risk of high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The kit of claim 4, wherein polysomy in ≧4 cells is indicative of high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract and tetrasomy in ≧11 cells, P16 loss in at least 5% of cells, single locus gain of MCL1, MYC or P16 in ≧8 cells, or single locus gain of MCL1, EGFR, or MYC with concurrent P16 loss in ≧4 cells infers increased risk of high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract."],"number":5,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}